Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BioXcel Therapeutics is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $18.86 |
|---|---|
| 52-week range | $8.80 - $34.13 |
| 50-day moving average | $28.65 |
| 200-day moving average | $17.85 |
| Wall St. target price | $55.18 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.40 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.86 from 2023-03-20
| 1 week (2023-03-14) | -7.23% |
|---|---|
| 1 month (2023-02-21) | -40.80% |
| 3 months (2022-12-21) | -10.66% |
| 6 months (2022-09-21) | 56.64% |
| 1 year (2022-03-21) | 12.20% |
|---|---|
| 2 years (2021-03-19) | -57.86% |
| 3 years (2020-03-20) | 9.27% |
| 5 years (2018-03-21) | 81.17% |
| Revenue TTM | $375,000 |
|---|---|
| Gross profit TTM | $355,000 |
| Return on assets TTM | -32.82% |
| Return on equity TTM | -95.08% |
| Profit margin | 0% |
| Book value | $4.53 |
| Market capitalisation | $549.3 million |
TTM: trailing 12 months
We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $8.795 up to $34.125. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.1931. This would suggest that BioXcel Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.